ArticleJournal of Cancer2025
Pan-Cancer Analysis of KANK2: Clinical and Molecular Insights into Tumor Progression and Therapeutic Implications.
Article in Journal of Cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Construction of a novel 3-gene diagnostic signature related to senescence in intervertebral disc degeneration.European journal of medical research · 2025Article
- Matrix Remodeling Associated Genes (MXRAs): structural diversity, functional significance, and therapeutic potential in tumor microenvironments.Discover oncology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundKANK2, a gene crucial for cell migration and movement, is implicated in neoplastic and non-neoplastic diseases. This study aimed to analyze KANK2's expression and its diagnostic and prognostic significance across 33 cancers using multiple online databases.
methodsThis study aimed to comprehensively analyze KANK2 in 33 cancers using The Cancer Genome Atlas (TCGA) and Genotype-Tissue Expression (GTEx) database. Multiple web platforms and software were used for data analysis, including R, Cytoscape, HPA, TISIDB, UALCAN, GEO, cBioPortal, STRING, GSCALite, and CancerSEA. WB and qPCR experiments were used to verify the results.
resultsKANK2 is widely expressed in various tissues and has significant diagnostic value in multiple cancers, with AUC values exceeding 0.75 in 13 cancer types. Survival analysis indicated that KANK2 expression is significantly associated with overall survival (OS) and disease-specific survival (DSS) in several cancers. KANK2 expression varied significantly across different molecular and immune subtypes and was associated with specific genetic mutations and DNA methylation patterns. Functional state analysis highlighted correlations with processes such as EMT, angiogenesis, and apoptosis. GSEA identified pathways related to proliferation, migration, and extracellular matrix remodeling. The key interacting proteins were identified by PPI network analysis, and the sensitive drug molecules were found by GSCA database. The results were also confirmed by two GEO datasets and WB and qPCR results.
conclusionKANK2 serves as a valuable biomarker for diagnosis and prognosis in various cancers, and its expression is intricately linked to multiple molecular and cellular processes, offering potential therapeutic targets for future research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.